Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aili Cao has a total of 82 co-authors. Here are the top co-authors by number of shared publications:

  • Li Wang

    Department of Nephrology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    5 shared publications
  • Ying Chen

    Department of Nephrology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    5 shared publications
  • Hao Wang

    Department of Nephrology, Laboratory of Renal Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    4 shared publications
  • Bingbing Zhu

    Department of Nephrology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

    3 shared publications
  • Bingbing Zhu

    Department of Nephrology, Laboratory of Renal Disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Ji Fang

    Department of Nephrology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Homozygous FAT1 frameshift mutation linked to glomerulotubular nephropathy with impaired cell adhesion and Rap1 signaling

    by Yang Fei, Zhouhui Jin, Li He, Meng Zhang, Qiong Jiao, Qiye Liu, Fujun Lin, Wei Wang, Niansong Wang, Aili Cao, et al.

    Genetic mutations are closely linked to various renal diseases, revealing important molecular mechanisms that contribute to kidney dysfunction. Here, we reported a 35-year-old Chinese female diagnosed of glomerulotubular nephropathy with multiple extra-renal manifestations including ptosis, corneal dystrophy, macular degeneration, right foot syndactyly. Whole-exome sequencing identified a homozygous frameshift variant in FAT1 (NM_005245: c.7444_7445delGT, p.Val2482AsnfsTer16). Further analysis revealed that this mutation caused translation repression of FAT1. RNA sequencing showed dysregulation of cell adhesion and Rap1 signaling pathways, while immunofluorescence staining demonstrated disrupted β-catenin junctions and cytoskeletal abnormalities in patient-derived primary urinary epithelial cells. Pull-down assays indicated that the reduction in activated Rap1 levels was correlated with the observed cellular defects. These findings provide compelling evidence that this loss-of-function homozygous FAT1 variant is causally associated with nephropathy and congenital anomalies, likely through degradation of transcribed mRNA and impaired protein expression. The results emphasize the critical role of FAT1 in renal development and provide new insights into the molecular mechanisms underlying these conditions.

  • Loss of ARNTL Enhances ER Stress and Apoptosis in CKD Through Disruption of NRF2 Signaling

    by Li He, Qunzi Zhang, Xiaohua Sheng, Jianyong Yin, Yan Yan, Mingyu Wu, Hongda Bao, Shuai Hu, Niansong Wang, Aili Cao

    Endoplasmic reticulum (ER) stress is a central driver of tubular cell apoptosis in chronic kidney disease (CKD), though the molecular pathways connecting ER stress to kidney injury remain unclear. In this study, we identify Aryl Hydrocarbon Receptor Nuclear Translocator‐Like (ARNTL) as a key regulator of the ER stress response and apoptosis in CKD, with significant implications for disease progression. ARNTL expression is markedly reduced in both CKD patients and CKD model mice, correlating with elevated markers of ER stress and reduced kidney function. In CKD patients, ARNTL expression in the kidney inversely correlates with serum creatinine and blood urea nitrogen levels, suggesting its protective role in maintaining renal health. Single‐cell sequencing further reveals that ARNTL is predominantly expressed in proximal tubular cells. In vitro studies demonstrate that the ER stress inducer tunicamycin (Tm) strongly suppresses ARNTL expression, whereas the ER stress inhibitor tauroursodeoxycholic acid (TUDCA) restores ARNTL levels and alleviates ER stress‐induced apoptosis, as indicated by reduced cleaved caspase‐3 and caspase‐9 levels. Notably, ARNTL silencing in HK2 cells intensifies ER stress, triggers mitochondrial apoptosis, promotes ROS production, and disrupts NRF2 activation. Moreover, ARNTL directly binds to the NRF2 promoter region and interacts with NRF2 through protein–protein binding. This study reveals the ARNTL‐NRF2 axis as a key protective pathway against stress‐induced injury in renal tubular cells, suggesting it as a promising therapeutic target for reducing tubular damage and inflammation in CKD.


  • Curcumin targets CXCL16-mediated podocyte injury and lipid accumulation in diabetic kidney disease treatment

    by Ying Chen, Jun Tao, Yijun He, Xudong Hou, Ji Fang, Jiebo Huang, Li Wang, Junlong Shen, Bingbing Zhu, Niansong Wang, et al.

    Among the complications of diabetes, diabetic kidney disease (DKD) frequently emerges, typified by the detrimental effects on renal function, manifesting through inflammation, dysregulated lipid metabolism, and harm to podocytes. Existing research underscores the significance of the soluble form of C-X-C chemokine ligand 16 (CXCL16) within the context of renal impairments. However, whether CXCL16 is involved in the pathogenesis of DKD remains elusive. We report that CXCL16 levels in the serum and kidneys of individuals with DKD were elevated and correlated with various lipid parameters. The expression of CXCL16 in human podocytes subjected to high glucose or palmitic acid induction and exogenous CXCL16 administration in these cells were examined. Higher CXCL16 levels were linked to abnormal lipid metabolism. Exogenous CXCL16 administration induced lipid droplets, microfilament disorganization, apoptosis, oxidative stress, and inflammation, inhibited PPAR γ, up-regulated COX2 expression, and inhibited Nrf2 translocation in podocytes. Molecular analysis revealed that Curcumin (Cur), a polyphenolic compound derived from Curcuma longa and an Nrf2 agonist, targets the ATP-binding pocket of CXCL16, inhibiting its kinase activity. Meanwhile, Cur therapy alleviated podocyte injury, lipid accumulation, improved glomerulopathy, and reduced albuminuria. Furthermore, after silencing CXCL16 expression in podocytes using siRNA, the effects of exogenous CXCL16 were nullified, and Cur no longer exhibited any significant impact. Thus, CXCL16 participates in the pathogenesis of DKD. Inhibition of CXCL16 has shown promising results in experimental models, suggesting its beneficial effects in ameliorating DKD.


  • The Potential of Huangqi Decoction for Treating Diabetic Kidney Disease

    by Ying Chen, Yang Liu, Aili Cao

    Diabetic kidney disease (DKD) is a prevalent complication of diabetes mellitus that primarily affects the kidney microvasculature. According to the Traditional Chinese Medicine (TCM) theory, early-stage DKD is characterized by deficiencies in essence and Qi and is often accompanied by spleen and kidney deficiencies. Huangqi decoction (HQD), a classic Chinese herbal formula with historical use in treating thirst-related ailments, is described in Shiyin Yang's Renzhai Zhizhi Fang Lun. This review aimed to investigate the potential molecular mechanisms, pharmacological effects, and key targets of HQD to establish a theoretical and scientific foundation for further research and clinical applications. The bioactive compounds and targets of HQD were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) database, and compound-target and protein-protein interaction networks were constructed using Cytoscape and BisoGent, respectively. A total of 172 bioactive compounds were identified in HQD. Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses of the hub targets indicated associations between diverse biological processes, cellular components, and molecular functions. These findings signify a promising avenue for the development of evidence-based treatments for DKD by leveraging the potential of TCM to enhance patient outcomes.


  • Open Access

    Huangqi decoction ameliorates kidney injury in db/db mice by regulating the BMP/Smad signaling pathway

    by Ying Chen, Rong Rui, Li Wang, Hao Wang, Bingbing Zhu, Aili Cao

    Purpose: This study aims to investigate the mechanism underlying the beneficial effects of Huangqi decoction (HQD) on Diabetic kidney disease (DKD) in diabetic db/db mice. Methods: Eight-week-old male diabetic db/db mice were randomly divided into four groups: Model (1% CMC), HQD-L (0.12 g/kg), HQD-M (0.36 g/kg), and HQD-H (1.08 g/kg) groups. Non-diabetic db/m mice were served as the control group. These mice received HQD treatment for 8 weeks. After treatment, the kidney function, histopathology, micro-assay, and protein expression levels were assessed. Results: HQD treatment improved the albumin/creatine ratio (ACR) and 24 h urinary albumin excretion, prevented the pathological phenotypes of increased glomerular volume, widened mesangial areas, the of mesangial matrix proliferation, foot process effacement, decreased nephrin expression and reduced number of podocytes. Expression profiling analysis revealed global transcriptional changes that predicted related functions, diseases and pathways. HQD treatment activated protein expressions of BMP2, BMP7, BMPR2, and active-Rap1, while inhibiting Smad1 and phospho-ERK. In addition, HQD was associated with improvements in lipid deposition in the kidneys of db/db mice. Conclusion: HQD ameliorated the progression of DKD in db/db mice by regulating BMP transcription and downstream targets, inhibiting the phosphorylation of ERK and the expression of Smad1, promoting Rap1 binding to GTP, and regulating the lipid metabolism. These findings provide a potential therapeutic approach for treating DKD.


  • Open Access

    Phosphorylation-dependent recognition of diverse protein targets by the cryptic GK domain of MAGI MAGUKs

    by Meng Zhang, Aili Cao, Lin Lin, Ying Chen, Yuan Shang, Chao Wang, Mingjie Zhang, Jinwei Zhu

    Dynamic signal transduction requires the rapid assembly and disassembly of signaling complexes, often mediated by phosphoprotein binding modules. The guanylate kinase-like (GK) domain of the membrane-associated guanylate kinases (MAGUKs) is such a module orchestrating signaling at cellular junctions. The MAGI subfamily of MAGUKs contains a truncated GK domain with unknown structure and function, although they participate in diverse physiological and pathological processes. Here, we demonstrate that the truncated GK domain of MAGI2 interacts with its adjacent PDZ0 domain to form a structural supramodule capable of recognizing phosphoproteins. A conserved phosphorylation-dependent binding motif for PDZ0-GK is delineated, which leads to identification of a set of previously unknown binding partners. We explore the structure and function of the MAGI2-target complex with an inhibitory peptide derived from the consensus motif. Our work reveals an action mechanism of the cryptic MAGI GKs and broadens our understanding of the target recognition rules of phosphoprotein binding modules.


  • Open Access

    Huangqi Decoction ameliorates kidney injury in db/db mice by regulating the BMP/Smad signaling pathway.

    by Ying Chen, Rong Rui, Li Wang, Hao Wang, Bingbing Zhu, Aili Cao

    Purpose Our study clarifies the mechanism of Huangqi decoction (HQD) against DKD in diabetic db/db mice. Methods Eight-week-old male diabetic db/db mice were randomly divided into four groups: Model (1% CMC), HQD-L (0.12 g/kg), HQD-M (0.36 g/kg), and HQD-H (1.08 g/kg) groups. Non-diabetic db/m mice were used as a control group. These mice received HQD treatment for 8 weeks continuously. After 8 weeks of feeding, kidneys were harvested to observe the kidney function, pathological changes, micro-assay study, and the protein expression levels. Results HQD treatment improved the albumin/creatine ratio (ACR) and 24 h urinary albumin, prevented the pathological phenotypes of increased glomerular volume, widened mesangial areas, the proliferation of mesangial matrix, the disappearance of foot processes, the decreased expression of nephrin and the number of podocytes. The expression profile chips were assessed to reveal the global transcriptional response and predict related functions, diseases and pathways. To verify this, we found that HQD treatment activated the protein expressions of BMP1, BMP7, BMPR2, and active-Rap1 and inhibited Smad1 and phospho-ERK. In addition, HQD could improve lipid deposition in the kidneys of db/db mice. Conclusion HQD prevents the progression of DKD in db/db mice by regulating the transcription of BMPs and their downstream target genes, inhibiting the phosphorylation of ERK and Smad1 by promoting the binding of Rap1 to GTP and regulating the lipid metabolism dysfunction. These provide a new idea for the treatment of DKD.

  • Open Access

    Zuogui Wan ameliorates high glucose-induced podocyte apoptosis and improves diabetic nephropathy in db/db mice

    by Bingbing Zhu, Ji Fang, Zhengcai Ju, Ying Chen, Li Wang, Hao Wang, Lina Xing, Aili Cao

    Zuogui Wan (ZGW), a well-known traditional Chinese medicine (TCM), has been used to nourish “Kidney-Yin” for a long time in China, implying a protective effect on the kidney. The aim of the present study is to investigate the effect of ZGW on high glucose-induced podocyte apoptosis and diabetic nephropathy (DN) in db/db mice. ZGW (1 g/kg−1/day−1) was administered intragastrically to db/db mice for 8 weeks. HPLC was used for identifying the components of ZGW, biochemical and histopathological approaches were used for evaluating its therapeutic effects, and cultured mouse podocytes were used for further exploring its underlying mechanism in vitro. ZGW improved renal function and podocyte loss and also normalized kidney reactive oxygen species production in db/db mice. The cytotoxicity of ZGW on mouse podocytes was assessed by the LDH assay. The effect of ZGW on podocyte viability and apoptosis was determined with CCK-8 and Annexin-V/PI staining by treatment with high glucose. ZGW attenuated podocyte apoptosis, and oxidative stress was detected by the peroxide-sensitive fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (DCF-DA) staining in a dose-dependent manner. Furthermore, ZGW decreased the expression of caspase-3 and phospho-p38 in both the kidney cortex and high glucose-treated podocytes. Thus, our data from in vivo and in vitro studies demonstrated that ZGW improved renal injury in diabetes by inhibiting oxidative stress and podocyte apoptosis.


  • Open Access

    DACH1 protects podocytes from experimental diabetic injury and modulates PTIP-H3K4Me3 activity

    by Aili Cao, Jianhua Li, Morad Asadi, John M. Basgen, Bingbing Zhu, Zhengzi Yi, Song Jiang, Tomohito Doke, Osama El Shamy, Niralee Patel, et al.

    Dachshund homolog 1 (DACH1), a key cell-fate determinant, regulates transcription by DNA sequence–specific binding. We identified diminished Dach1 expression in a large-scale screen for mutations that convert injury-resistant podocytes into injury-susceptible podocytes. In diabetic kidney disease (DKD) patients, podocyte DACH1 expression levels are diminished, a condition that strongly correlates with poor clinical outcomes. Global Dach1 KO mice manifest renal hypoplasia and die perinatally. Podocyte-specific Dach1 KO mice, however, maintain normal glomerular architecture at baseline, but rapidly exhibit podocyte injury after diabetes onset. Furthermore, podocyte-specific augmentation of DACH1 expression in mice protects from DKD. Combined RNA sequencing and in silico promoter analysis reveal conversely overlapping glomerular transcriptomic signatures between podocyte-specific Dach1 and Pax transactivation-domain interacting protein (Ptip) KO mice, with upregulated genes possessing higher-than-expected numbers of promoter Dach1-binding sites. PTIP, an essential component of the activating histone H3 lysine 4 trimethylation (H3K4Me3) complex, interacts with DACH1 and is recruited by DACH1 to its promoter-binding sites. DACH1-PTIP recruitment represses transcription and reduces promoter H3K4Me3 levels. DACH1 knockdown in podocytes combined with hyperglycemia triggers target gene upregulation and increases promoter H3K4Me3. These findings reveal that in DKD, diminished DACH1 expression enhances podocyte injury vulnerability via epigenetic derepression of its target genes.


  • Open Access

    Transcriptome-wide association analysis identifies DACH1 as a kidney disease risk gene that contributes to fibrosis

    by Tomohito Doke, Shizheng Huang, Chengxiang Qiu, Hongbo Liu, Yuting Guan, Hailong Hu, Ziyuan Ma, Junnan Wu, Zhen Miao, Xin Sheng, et al.

    Genome-wide association studies (GWAS) for kidney function identified hundreds of risk regions; however, the causal variants, target genes, cell types, and disease mechanisms remain poorly understood. Here, we performed transcriptome-wide association studies (TWAS), summary Mendelian randomization, and MetaXcan to identify genes whose expression mediates the genotype effect on the phenotype. Our analyses identified Dachshund homolog 1 (DACH1), a cell-fate determination factor. GWAS risk variant was associated with lower DACH1 expression in human kidney tubules. Human and mouse kidney single-cell open chromatin data (snATAC-Seq) prioritized estimated glomerular filtration rate (eGFR) GWAS variants located on an intronic regulatory region in distal convoluted tubule cells. CRISPR-Cas9–mediated gene editing confirmed the role of risk variants in regulating DACH1 expression. Mice with tubule-specific Dach1 deletion developed more severe renal fibrosis both in folic acid and diabetic kidney injury models. Mice with tubule-specific Dach1 overexpression were protected from folic acid nephropathy. Single-cell RNA sequencing, chromatin immunoprecipitation, and functional analysis indicated that DACH1 controls the expression of cell cycle and myeloid chemotactic factors, contributing to macrophage infiltration and fibrosis development. In summary, integration of GWAS, TWAS, single-cell epigenome, expression analyses, gene editing, and functional validation in different mouse kidney disease models identified DACH1 as a kidney disease risk gene.